PEARL RIVER, NY – Pfizer and BioNTech are on track to seek regular evaluation of their mRNA-based vaccine program, BNT162b2, as early as October 2020.
Once authorization as regulatory approval is obtained, the companies plan to deliver 100,000 doses worldwide by the end of 2020 and about 1.3 billion doses by the end of 2021, Pfizer officials said.
The companies yesterday released new data that helped inform Pfizer and BioNTech’s decision to select BNT162b2 as the main candidate to continue in pivotal trials.
“We are proud to share our findings with the scientific community as we continue our work to provide a safe and effective vaccine to combat this devastating virus,” said Pearl River, NY-based Kathrin Jansen, senior vice president. President and Head of Vaccine Research & Development at Pfizer Inc. told Patch. “We are particularly pleased to present this early data showing the promising safety and immunogenicity profile of our vaccine candidate from the US trial and we look forward to sharing data from the German trial’s T immune response in the US trial. whole future. “
